Overview

BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer

Status:
Recruiting
Trial end date:
2034-09-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Illinois at Chicago
Treatments:
Capecitabine
Cyclophosphamide
Methotrexate